Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this case-based panel discussion on the role of CDK 4/6 inhibitors in clinical practice.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications. It is also helpful in reducing or eliminating endocrine resistance when used in combination with endocrine therapy. It can be used for the treatment of hormone receptor–positive (HR+) breast cancer.
The CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib are observed to enhance the change in the treatment paradigm for patients with HR+/HER2− advanced breast cancer. Moreover, these drugs have demonstrated a meaningful improvement in PFS when used for first- or later-line therapy.
Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Survival rates for incurable larynx cancer investigated for first time
2.
findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.
3.
Knowing about and avoiding bladder cancer.
4.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
5.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
1.
Evidence-Based Approaches in Hematology for Modern Medicine
2.
Citizen-Centered Digital Health Navigation Systems: Advancing Patient Engagement and Optimizing Healthcare Delivery
3.
Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After
4.
The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
5.
Thromboprophylaxis In Medical Settings
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge